Jordan K. Paradise, J.D.
Curriculum Vitae

Schering-Plough Professor of Law
Seton Hall University School of Law
One Newark Center, 514
Newark, New Jersey 07102
Tel.: 973-642-8825
Email: jordan.paradise@shu.edu
SSRN Author page: http://papers.ssrn.com/author=512260

EDUCATION

Chicago-Kent College of Law, Chicago, Illinois
Juris Doctor, May 2003; Intellectual Property Law Certificate

University of Michigan, Ann Arbor, Michigan
Bachelor of Science, Biological Psychology & Cognitive Science, April 1999

ADMISSIONS

State Bar of Illinois, November 2003

HONORS & AWARDS

Chicago-Kent College of Law Merit Scholarship
Chicago-Kent College of Law Fellowship
Chicago-Kent College of Law Dean's List
1st Place, Food & Drug Law Institute H. Thomas Austern Memorial Student Writing Competition 2003
Campbell Foundation Scholarship (University of Michigan)
Cook Family Foundation Scholarship (University of Michigan)
University of Michigan, LSA Dean's List

PROFESSIONAL EXPERIENCE

Seton Hall University School of Law, Newark, NJ, July 2009-present
- **Schering-Plough Professor of Law**, July 2014-present
- **Associate Professor of Law**, July 2009-June 2014

University of Minnesota Law School, Minneapolis, MN, June 2005-June 2009
- **Associate Director of Research and Education**
  Joint Degree Program in Law, Health & the Life Sciences
  Consortium on Law and Values in Health, Environment & the Life Sciences
- **Adjunct Associate Professor of Law**
- **Faculty Editor-in-Chief**, December 2006-June 2009
- **Faculty Managing Editor**, April 2006-December 2006
- **Faculty Editorial Advisory Board Member**, June 2005-April 2006
  Minnesota Journal of Law, Science and Technology

University of Minnesota, Minneapolis, MN, June 2005-June 2009
- **Associate Researcher** (joint appointment)
  Center for Bioethics, University of Minnesota Academic Health Center
- **Adjunct Professor**, September 2008-December 2008 (joint appointment)
  Hubert H. Humphrey Institute of Public Affairs

Illinois Institute of Technology/Chicago-Kent College of Law, Chicago, IL, January 2001-May 2005
- **Legal Fellow**, August 2003-May 2005
  Institute for Science, Law and Technology

Policy Analyst, March 2004-May 2005
Institute on Biotechnology and the Human Future
Research Assistant, January 2001-August 2003
Professor Lori Andrews

University of Michigan, Ann Arbor, MI, March 1999-August 2000
Laboratory Technician
Dr. Kent Berridge (Neuroscience Department)

TEACHING

Seton Hall University School of Law

- Administrative Law
- Emerging Technologies Law
- Food & Drug Law
- Law & Genetics
- Law & the Life Sciences

University of Minnesota Law School (Fall 2005-2008)

- Law, Health & the Life Sciences
- Nanotechnology & Society, University of Minnesota
- Select lectures for BSE 3305: Introduction to Bioethics

PUBLICATIONS

LAW REVIEW ARTICLES

No Sisyphean Task: How the FDA Can Regulate Electronic Cigarettes, 13 YALE J. HEALTH POL'Y, L. & ETHICS 326-74 (2013).

Synthetic Biology: Does Re-writing Nature Require Re-writing Regulation?, 117 PENN. ST. L. REV. 53-88 (2012)(with Ethan Fitzpatrick).

Reassessing 'Safety' for Nanotechnology Combination Products: What Do 'Biosimilars' Add to Regulatory Challenges for the FDA?, 56 ST. LOUIS U. L. J. 1-55 (2012).

Claiming Nanotechnology: Improving USPTO Efforts at Classification of Emerging Nano-Enabled Pharmaceutical Technologies, 10(3) NW. J. TECHNOL. & INTELL. PROP. 169-207 (2012).

Follow-On Biologics: Implementation Challenges and Opportunities, 41 SETON HALL L. REV. 501-509 (2011).

Exploring Emerging Nanobiotechnology Drugs and Medical Devices, 63(2) FOOD & DRUG L. J. 407-420 (2008)(with Gail M. Diliberto, Alison W. Tisdale & Efrosini Kokkoli).

Developing Oversight Frameworks for Nanobiotechnology, 9(1) MINN. J. L. SCI. & TECH. 187-203 (2008)(with Susan M. Wolf, Gurumurthy Ramachandran, Efrosini Kokkoli, Ralph Hall & Jennifer Kuzma).

Tales from the Crypt: Scientific, Ethical, and Legal Considerations for Biohistorical Analysis of Deceased Historical Figures, 26 TEMPLE J. SCI., TECH. & ENV'TL L. 223-299 (Fall 2007)(with Lori B. Andrews).

Gene Patents: The Need for Bioethics Scrutiny and Legal Change, 5 YALE J. HEALTH POL'Y, L. & ETHICS 403-412 (2005)(with Lori B. Andrews).

Lessons from the European Union: The Need for a Post-Grant Mechanism for Third Party Challenge to U.S. Patents, 7(1) MINN. J. L. SCI. & TECH. 315-326 (2005).

European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent Controversy, 59(1) FOOD & DRUG L. J. 133-154 (2004).

PEER-REVIEWED ARTICLES (SCIENTIFIC, BIOETHICS, LEGAL & PUBLIC POLICY PUBLICATIONS)

Electronic Cigarettes: Smoke-Free Laws, Use Restrictions, and the Public Health, 104 AM. J. PUB. HEALTH e17 (2014).

The Devil is in the Details: Health Care Reform, Biosimilars, and Implementation Challenges for the Food and Drug Administration, 51 JURIMETRICS 279-292 (2011).

Recommendations for Oversight of Nanobiotechnology: Dynamic Oversight for Complex and Convergent Technologies, 13(4) J. NANOPARTICLE RES. 1345-71(APRIL 2011)(with Gurumurthy Ramachandran, Susan M. Wolf, Jennifer Kuzma, Ralph Hall, Efrosini Kokkoli, & Leili Fatehi).

The Challenge of Developing Oversight Approaches to Nanobiotechnology, 37(4) J. LAW, MED. & ETHICS 543-545 (2009)(with Susan M. Wolf, Jennifer Kuzma, Gurumurthy Ramachandran & Efrosini Kokkoli).

Evaluating Oversight of Human Drugs and Medical Devices: A Case Study of the FDA and Implications for Nanobiotechnology, 37(4) J. LAW, MED. & ETHICS 598-624 (2009)(with Alison W. Tisdale, Ralph Hall & Efrosini Kokkoli).

Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences, 37(4) J. LAW, MED. & ETHICS 688-705 (2009)(with Susan M. Wolf, Jennifer Kuzma, Aliya Kuzhabekova, Alison W. Tisdale, Gurumurthy Ramachandran & Efrosini Kokkoli).

Patient Advocacy Group Collaboration in Genetic Research and The Scope of Joint Inventorship under U.S. Patent Law, 3(2) INTERNAT'L J. INTELL. PROP. MANAGEMENT 97-109 (2009).

An Integrated Approach to Oversight Assessment for Emerging Technologies, 28(5) RISK ANALYSIS 1197-1220 (2008)(with Jennifer Kuzma, Gurumurthy Ramachandran, Jee-Ae Kim, Adam Kokotovich & Susan M. Wolf).

The Law of Incidental Findings in Human Subjects Research, 36(2) J. LAW, MED. & ETHICS 361-383 (2008)(with Susan M. Wolf & Charlisse Caga-anan).

Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations, 36(2) J. LAW, MED. & ETHICS 219-248 (2008)(with Susan M. Wolf, Frances P. Lawrenz, Charles A. Nelson, Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton, Joel G. Fletcher, Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Lisa S. Parker, Sharon F. Terry, Brian Van Ness & Benjamin S. Wilfond).

When Patents Threaten Science, 314 SCI. 1395-96 (2006)(with Lori B. Andrews, Timothy Holbrook & Danielle Bochneak).

Decoding the Research Exemption, 7(2) NAT. REV. GENET. 148-154 (2006)(with Christopher Janson).

Problems in Patenting Human Genes, 308 SCI. 1869 (2005)(with Lori B. Andrews & Timothy Holbrook).

Call for Biohistory Guidelines, 2 PLOS MEDICINE e192 (2005).

Patents on Human Genes: An Analysis of Scope and Claims, 307 SCI. 1566-1567 (2005)(with Lori B. Andrews & Timothy Holbrook).

Constructing Ethical Guidelines for Biohistory, 304 SCI. 214-215 (2004)(with Lori B. Andrews, Nancy Buenger, Jennifer Bridge, Laurie Rosenow, David Stoney, R.E. Gaensslen, Theodore Karamanski, Russell Lewis, Amy Inlander & David Gonen).

SHORTER ARTICLES

Human Genome Research and Return of Research Results, ENCYCLOPEDIA OF BIOETHICS, 4th Ed., Bruce Jennings, Ed. (Macmillan, 2014).

Another Victory for Laws of Nature, Abstract Ideas, and Natural Phenomenon, HEALTH REFORM WATCH.COM (June 19, 2014).

FDA Debuts OpenFDA Database, HEALTH REFORM WATCH.COM (June 18, 2014).

What the FDA's Deeming Regulations Mean for E-Cigarettes, HEALTH REFORM WATCH.COM (May 21, 2014).

State's Tackle Biosimilar Substitution, HEALTH REFORM WATCH.COM (Mar. 19, 2014).

FDA's Proposed Changes to Generic Drug Label Rules Questioned by Members of Congress, HEALTH REFORM WATCH.COM (Jan. 29, 2014).

The Trans Fat Smackdown, HEALTH REFORM WATCH.COM (Nov. 11, 2013).

Funding, and Ethics, for the BRAIN Initiative, HEALTH REFORM WATCH.COM (Oct. 1, 2013).

FDA Regulation of Microbes Modified Using Synthetic Biology in Drugs and Cosmetics, commissioned by the J. Craig Venter Institute Policy Center, Rockville, MD, 2013.

Book Review of PRABUDDHA GANGULI & SIDDHARTH JABADE, NANOTECHNOLOGY INTELLECTUAL PROPERTY RIGHTS: RESEARCH, DESIGN, AND COMMERCIALIZATION, 34(4) WORLD PATENT INFORMATION 319-320 (2012).

Nanobiotechnology and the FDA, Food and Drug Law Institute's UPDATE MAGAZINE (March/April 2010).

FDA is Taking Baby Steps toward Regulating Nanotechnology, HEALTH REFORM WATCH.COM (June 13, 2011).

Banning Gene Patents Can Bring Benefits, 1(39) BIOWORLD TODAY , September 20, 2007(with Lori B. Andrews).

National Conference on Research Cloning, PERSPECTIVES: THE MAGAZINE FOR THE UNIVERSITY OF MINNESOTA LAW SCHOOL (Spring 2007).

The Risks Posed by New Biomedical Technologies: How Do We Analyze, Communicate & Regulate Risk?, 13(3) LAHEY CLINIC MED. ETHICS J. 5-8 (Fall 2006)(with Susan M. Wolf, Eds.).

BOOK CHAPTERS & SYMPOSIA

Introduction to Biologics, Chapter 3 in THE FUNDAMENTALS OF LIFE SCIENCES LAW: DRUGS, DEVICES, AND BIOTECH, 2nd Ed. (American Health Lawyers Association, 2014).

Genetic Sequence Patents: Historical Justification and Current Impacts, in Jean-Paul Gaudillière, Daniel J. Kevles, Hand-Jörg Rheinberger, eds., LIVING PROPERTIES: MAKING KNOWLEDGE AND CONTROLLING OWNERSHIP IN THE HISTORY OF BIOLOGY 137- 163(Max Planck Institute for the History of Science: Paris 2009)(with Lori B. Andrews).

DEVELOPING OVERSIGHT APPROACHES TO NANOBIOTECHNOLOGY: THE LESSONS OF HISTORY, 37(4) J. LAW, MED. & ETHICS (2009)(with Susan M. Wolf, Gurumurthy Ramachandran & Jennifer Kuzma, Eds.).

INCIDENTAL FINDINGS IN HUMAN SUBJECTS RESEARCH: FROM IMAGING TO GENOMICS, 36(2) J. LAW, MED. & ETHICS 216-383 (2008)(with Susan M. Wolf, Charles A. Nelson, Jeffrey P. Kahn & Francis Lawrenz, Eds.).

Gene Patents and Bioethics in TOWARDS A DECLARATION ON UNIVERSAL NORMS ON BIOETHICS EXTRAORDINARY SESSION OF THE INTERNATIONAL BIOETHICS COMMITTEE, Paris, April 27-29, 2004 (with Lori B. Andrews).

SELECTED PRESENTATIONS

COMPETITIVELY SELECTED

The Gen-Nano-Neuro Convergence, Food & Drug Law Institute and Harvard Law School, Emerging Issues and New Frontiers for FDA Regulation, *forthcoming* Washington, D.C., Oct. 20, 2014.

Is One of These Things Not Like the Other?: Biosimilar Naming and Substitution Challenges, American Society of Law, Medicine & Ethics 37th Annual Health Law Professors Conference, San Francisco, CA, June 7, 2014.

Different Risk, Different Name?: The Debate over Nonproprietary Naming of Biosimilar Biologics, Arizona State University Sandra Day O'Connor School of Law, 1st Annual Governance of Emerging Technologies: Law, Policy, and Ethics, Phoenix, AZ, May 21, 2013.

A Sisyphean Task?: How the FDA Can Effectively Utilize the Tobacco Control Act to Regulate Electronic Cigarettes, AALS Annual Meeting, New Voices in Administrative Law, New Orleans, LA, Jan. 5, 2013.

Is it Science? Is it Engineering? Is it Safe?, American Society of Law, Medicine & Ethics 35th Annual Health Law Professors Conference, Tempe, AZ, June 8, 2012.

Current Legal Status of Follow-On Biologics, American Society of Law, Medicine & Ethics 33d Annual Health Law Professors Conference, Austin, TX, June 4, 2010.

The FDA, Nanodrugs, and Implications for Healthcare, American Society of Law, Medicine & Ethics 32nd Annual Health Law Professors Conference, Cleveland, OH, June 5, 2009.

Oversight Challenges for Drugs and Medical Devices at the Nanoscale, Institute of Nanotechnology, 21st Century Medicine: Breakthroughs and Challenges, London, U.K., Nov. 26, 2008.

Tales from the Crypt: Scientific, Ethical, and Legal Considerations for Biohistorical Analysis of Deceased Historical Figures, Case Western Reserve University, Center for Genetics Research Ethics and Law, Translating ELSI: Ethical, Legal and Social Implications of Genomics Conference, Cleveland, OH, May 1, 2008.

Ethical, Legal & Scientific Issues with Incidental Findings in Human Subjects Research, Genetic Alliance 2007 Annual Conference, Bethesda, MD, July 28, 2007 (with Bonnie LeRoy & Suzanne Sobotka).

INVITED PRESENTATIONS

Keynote Address: Three Challenges to Pharmacovigilance, Sidley Austin Pharmacovigilance (pv) Legal, Whippany, NJ, July 16, 2014.

Nanotechnology Law & Policy, Earth Justice, New York, NY, June 11, 2014.

Emerging Life Sciences, Lafayette College, Easton, PA, April 29, 2014.

Panel Member, *FDA Hot Topics,* Sidley Austin Life Science College, New York, NY, April 3, 2014.

The BRAIN Initiative: Law, Policy, Ethics, Lehigh University, Bethlehem, PA, Nov. 21, 2013.

The BRAIN Initiative: Law, Policy, Ethics, New Jersey Institute of Technology, Newark, NJ, Nov. 6, 2013.

Working in the Food and Drug Law Space: Challenges and Opportunities, Food and Drug Law Institute Annual Conference, Washington, D.C., Apr. 24, 2013.

Gene Patents at the Supreme Court, New Jersey Institute of Technology, Newark, NJ, Apr. 17, 2013.

FDA I & II: Pharmaceutical Regulatory and Compliance Fundamentals, Sidley Austin Life Sciences College, New York, NY, Feb. 26, 2013.

Implementation of the Biologics Price Competition and Innovation Act, Gibbons PC and Institute for Law, Science & Technology, Newark, NJ, Feb. 19, 2013.

An Overview of the Food & Drug Administration, Seton Hall MSJ Open House, Newark, NJ, Oct. 20, 2012.

Panel Moderator, CBER Developments, Food & Drug Law Institute, 55th Annual Conference, Washington, D.C., Apr. 24, 2012.

Assessing FDA Regulation of New Drugs, Animal Drugs, and Cosmetics As Applied to Microbes Modified Using Synthetic Biology, J. Craig Venter Institute, Rockville, MD, Jan. 31, 2012.

The Devil is in the Details: Health Care Reform, Biosimilars, and Implementation Challenges for the Food and Drug Administration, 3rd Annual Pharmaceutical Reimbursement & Market Access Conference, Philadelphia, PA, Oct. 28, 2011.

Sottera v. FDA: Electronic Cigarettes and the Tobacco Control Act of 2009, Food & Drug Law Institute, 54th Annual Conference, Washington, D.C., Apr. 6, 2011.

Panel Member, *Synthetic Biology Meets the Law,* AALS Annual Meeting, Biolaw Section, San Francisco, CA, Jan. 5, 2011.

The Biologics Price Competition and Innovation Act: FDA and Biosimilars, Seton Hall University School of Law, Follow-On Biologics: Implementation Challenges and Opportunities Roundtable, Newark, NJ, Oct. 29, 2010.

Health Care Reform Challenges for FDA -- Follow-On Biologics, Seton Hall MSJ Open House, Newark, NJ, Oct. 23, 2010.

Developing Oversight for Nanobiotechnology: Human Drugs and Medical Devices, University of Massachusetts, Nanotechnology & Society: Emerging Organizations, Oversight, and Public Policy Systems Conference, Amherst, MA, Sept. 24, 2010.

Consensus Recommendations on Nanobiotechnology Oversight, Governing Nanobiotechnology: Reinventing Oversight in the 21st Century Conference, University of Minnesota, Minneapolis, MN, Apr. 15, 2010.

Joe Camel, The Marlboro Man, and the FDA: Implementing the 2009 Tobacco Legislation, Seton Hall MSJ Open House, Newark, NJ, Mar. 6, 2010.

Regulating Nanotechnology, Panel member, Food and Drug Law Institute Second Annual Nanotechnology Conference, Washington, D.C., Feb. 19, 2009.

Intellectual Property, Innovation, and Genetics, University of Minnesota, GCD 8914: Ethical & Legal Issues in Genetic Counseling, Minneapolis, MN, Feb. 13, 2009.

Nanotechnology in the Life Sciences, Biology, Society & Environment 3305: Introduction to Bioethics, Minneapolis, MN, Nov. 18, 2008.

Patent Implications for Genetic Counseling, Minnesota Genetic Counselors, Landscape Arboretum, Chaska, MN, Nov. 7, 2008.

Synthetic Biology: Balance Between Scientific Innovation and Security, Commentator, Lecture Series in Law, Health & the Life Sciences, Minneapolis, MN, Nov. 4, 2008.

What's the Problem with Gene Patents? Biology, Society & Environment 3305: Introduction to Bioethics, Minneapolis, MN, Oct. 16, 2008.

Intellectual Property and the U.S. Constitution, Public Affairs 5701: Science & State, Minneapolis, MN, Oct. 6, 2008.

Scientific and Regulatory Issues in Nanobiotechnology: Exploring Nanodrugs and Nanodevices, University of Minnesota, Materials Research Science and Engineering Center, Research Experience for Undergraduates, Minneapolis, MN, July 23, 2008.

Nanotechnology: Ethical, Social and Legal Issues, University of Minnesota, Life Sciences Summer Undergraduate Research Program, Minneapolis, MN, July 14, 2008.

Tales from the Crypt: Scientific, Ethical, and Legal Considerations for Biohistorical Analysis of Deceased Historical Figures, Case Western Reserve University, Center for Genetics Research Ethics and Law, Translating ELSI: Ethical, Legal and Social Implications of Genomics conference, Cleveland, OH, May 1, 2008.

Patent Pending: Rights and Roles of Patients and Human Subjects in Commercialization of Genetics Research, University of Minnesota, BTHX5325/Phil 5325: Biomedical Ethics, Minneapolis, MN, Apr. 29, 2008.

Gene Patents & Biobanks: Law & Policy, University of Minnesota, GCD 8914: Ethical & Legal Issues in Genetic Counseling, Minneapolis, MN, Feb. 22, 2008.

Developing Oversight Mechanisms for Nanobiotechnology, National Science Foundation, NIRT Investigators meeting, Arlington, VA, Dec. 3, 2007.

Article 1: The Basis of Intellectual Property Rights, Public Affairs 5701: Science & State, Minneapolis, MN, Oct. 8, 2007.

FDA & Nanomedicine: Nanodrugs & Nanodevices, Nanoscale Interdisciplinary Research Team (NIRT) Working Group Meeting, Minneapolis, MN, Oct. 4, 2007.

Patent Law & Policy in Genetics, University of Minnesota, BIOC8401: Careers, Policy & Ethics in Biomedicine, Minneapolis, MN, Mar. 19, 2007.

FDA and Nanobiotechnology: Regulatory Issues & Capacity, National Science Foundation Investigators Meeting, Arlington, VA, Mar. 16, 2007.

Gene Patents & Biobanks: Law & Policy, University of Minnesota, GCD 8914: Ethical & Legal Issues in Genetic Counseling, Minneapolis, MN, Feb. 16, 2007.

Food & Drug Administration: Oversight of Drugs and Medical Devices, Nanoscale Interdisciplinary Research Team (NIRT) Working Group Meeting, Minneapolis, MN, Jan. 16, 2007.

Patent Law and Policy in Human Genetics, University of Minnesota, GCD 8073: Advanced Human Genetics, Minneapolis, MN, May 5, 2006.

Intellectual Property & Genetics, University of Minnesota, BIOC8401: Careers, Policy & Ethics in Biomedicine, Minneapolis, MN, Mar. 27, 2006.

Gene Patents & Biobanks: Law, Policy, Problems, University of Minnesota, GCD 8914: Ethical & Legal Issues in Genetic Counseling, Minneapolis, MN, Mar. 10, 2006.

Problems with Gene Patents, University of Minnesota Law School, Law 6875: Law, Health & the Life Sciences, Minneapolis, MN, Sept. 7, 2005.

Genetic Modifications: Ethical, Legal and Social Implications, Chicago-Kent College of Law, Reproductive Technology Seminar, Chicago, IL, Apr. 7, 2005.

Gene Patents and Intellectual Property, University of Minnesota Law School, Minneapolis, MN, Jan. 27, 2005.

GRANT INVOLVEMENT

National Human Genome Research Institute, Grant # R01 HG005171, *Federal Regulation of Probiotics: An Analysis of Existing Regulatory Frameworks*, September 4, 2009-June 30, 2012 (PI: Diane Hoffmann). Role: Working Group Member.

National Institutes of Health & National Human Genome Research Institute, Grant # RC1 HG005338 01, *Nanodiagnostics and Nanotherapeutics: Building Research Ethics and Oversight*, September 30, 2009-July 31, 2012. (PI: Susan M. Wolf). Funded Role: Co-Investigator. [Project role declined after funding award as result of employment change.]

National Science Foundation, Grant # 0608791, *NIRT: Evaluating Oversight Models for Active Nanostructures and Nanosystems: Learning from Past Technologies in a Societal Context*, September 2006-August 2010. (PI: Susan M. Wolf). Role: Co-Principal Investigator.

The Greenwall Foundation, *Emerging Problems in Neurogenomics: Ethical, Legal & Policy Issues at the Intersection of Genomics & Neuroscience*, November 1, 2007-May 31, 2008. (I: Susan M. Wolf). Role: Co-Investigator.

National Institutes of Health, Grant 5R01HG003178, *Managing Incidental Findings in Human Subjects Research*, September 2005-July 2007 (PI: Susan M. Wolf). Role: Working Group Member.

Robert Wood Johnson Foundation, Grant 047723, *Impact of Gene Patents on the Delivery of Health Care Services*, September 2003-August 2005 (PI: Lori Andrews). Role: legal researcher and policy analyst.

Department of Energy, Grant DE-FG02-02ER63460, *Complex Genetic Disorders and Intellectual Property Rights*, September 2002-August 2005 (PI: Lori Andrews & Timothy Holbrook). Role: legal researcher and policy analyst.

National Science Foundation, Grant 0134850, *Ethical, Legal, and Technical Issues of Biohistorical Research*, June 2002-May 2004 (PI: Lori Andrews). Role: legal researcher and policy analyst.

INSTITUTIONAL SERVICE

UNIVERSITY

Faculty Convocation Committee, Fall 2012, Fall 2013
Graduate Policy Advisory Committee, 2012-2014

LAW SCHOOL

Curriculum Committee, 2009-2013
DASC, 2009-2014 (Chair, 2011-2014)
Information Technology Committee, 2013-2014
Legal Writing and Skills Subcommittee, 2011-2012
Super-Adjunct Search Committee, 2012

AFFILIATIONS

PROFESSIONAL MEMBERSHIPS

Association of American Law Schools (Law, Medicine & Health Section)
American Bar Association (Science and Technology Section)
American Society of Law, Medicine & Ethics
Food and Drug Law Institute
Illinois State Bar Association

PROFESSIONAL PEER REVIEW

Peer reviewer for OXFORD UNIVERSITY PRESS; SCIENCE; JURIMETRICS; KENNEDY INSTITUTE OF ETHICS JOURNAL; LAHEY JOURNAL OF MEDICAL ETHICS; AMERICAN JOURNAL OF PUBLIC HEALTH; PERSPECTIVES IN BIOLOGY AND MEDICINE; IRB: ETHICS & HUMAN RESEARCH; YALE JOURNAL OF HEALTH POLICY, LAW & ETHICS; HEALTH AFFAIRS; JOURNAL OF GENETIC COUNSELING; SCRIPT-ED; and WORLD PATENT INFORMATION.